Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY
Dr. Reddy's Laboratories — Q4 FY26 Earnings Presentation
17 slides from Dr. Reddy's Laboratories's earnings presentation, May 12, 2026
Slide 1: Q4 & FY26 Results Update
(3 Dr. Reddy’s Q4 & FY26 RESULTS UPDATE 12 MAY 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement Dr.Reddy’s Q This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying ass
Slide 3: Q4FY26 Financial Highlights
Q4FY26 Financial Highlights Dr.Reddy's Q Double-digit growth in base business’ and 19.5% EBITDA Margin before impact of specific items Reported Revenues 27,516 cr FINANCIALS EXCLUDING SPECIFIC ITEMS Przwyvoy F 14%Q00 EBITDA | EBITDA % 7.260 | HME erie excusing spect tems 2981 cr) 13% : HEE Fovison f
Slide 4: FY26 Financial Highlights
FY26 Financial Highlights Dr.Reddy’s Performance aided by double-digit base business’ growth, acquired NRT business & productivity efforts before impact _Of specific items Reported Revenues 233,593 cr BE s%Y0Y FINANCIALS EXCLUDING SPECIFIC ITEMS HE Financials exctuding speciic items EBITDA | EBEDAS
Slide 5: Business Highlights
Q4FY26 Business Highlights Dr.Reddy's Q Steady progress across strategic priorities + Dr. Reddy's becomes 1 company to secure approval for generic semaglutide injection for Type 2 Diabetes in Canada + Day 4 launch of generic semaglutide injection under brand name, ‘Obeda® in India. + Secured approva
Slide 6: Other Highlights
Q4FY26 Other Highlights Dr.Reddy’s Q ESG ecovadis + Gold Medal by EcoVadis for FY26, achieving our highest-ever score of 80, placing us among top 5% companies assessed globally. + Among India’s Top 5 Most Sustainable Companies by BusinessWorld, #1 in Indian healthcare & pharmaceutical ivisc industry
Slide 7: Revenue Split
Q4FY26 Revenue Split Dr.Reddy’s Broad-based growth ex. US, supported by forex; moderated by lower lenalidomide sales and SSA REVENUE BY SEGMENT GLOBAL GENERICS SPLIT North America Europe 21,756 cr 21,452 cr GLOBAL GENERICS 88% Sevwey B smaca =—______ Overall* BP sixvoy F a1%a00 Beever cance 6 19% 27
Slide 8: FY26 Revenue Split
FY26 Revenue Split Dr.Reddy’s Double digit growth across geographies, except North America due to product-specific headwinds REVENUE BY SEGMENT GLOBAL GENERICS SPLIT North America Europe GLOBAL GENERICS z 11,374 Cr z 5,550 Cr 89% Son F220 AP ss%yoy" Overall* ° ») a” 34% g PSAI 10% ; » OTHERS bated I
Slide 9: Key Financial Metrics
Key Financial Metrics Dr.Reddy's Q Sustaining growth & profitability, while investing for the future REVENUES GROSS MARGINS SG&A R&D EBITDA MARGINS (eer) (% of Revenues) (% of Revenues) ((% of Revenues) (% of Revenues) -O4FY26 NM 7,516 *O4FY25 MN 44.8% -O4Fy25 NNN 36.9% °OFY25 NNN 7.3% -O4FY26 MM 13
Slide 10: North America Performance
Q4FY26 North America Performance Dr.Reddy’s Impacted by lower sales and shelf stock adjustment of lenalidomide ~ MARKET PERFORMANCE KEY UPDATES 23% 0 0, oe vs 0.8% «First company to secure approval for generic semagute injection for (Excl, Lenalidomide) i “As perlQViA MAT Fb’ 28 Type 2 Diabetes in C
Slide 11: Emerging Markets Performance
Q4FY26 Emerging Markets Performance Dr.Reddy’s New product launches, higher volume uptake and favourable forex driving growth KEY UPDATES ws COUNTRIES PRESENT IN + Launched Tegoprazan in Russia 48 gop! + Submitted responses to ANVISA in Brazil to address concerns w.rt. NEW PRODUCT LAUNCHES ‘our gene
Slide 12: India Performance
Q4FY26 India Performance Sustained double-digit growth, continued outperformance of IPM 21% Revenues 21,566 cr 20%YOY 2%G0a Growth Drivers : Innovation portfolio, new brand launches, price increases, higher volumes & acquisitions (Stugeron, Progynova). Historical Revenues (% Cr) ys TT 1,566 asFy26 1
Slide 13: Europe Performance
Q4FY26 Europe Performance Dr.Reddy’s Momentum in new launches, aided by forex tailwinds, moderated by pricing pressure i, KEY UPDATES EU COUNTRIES PRESENT IN + NRT integration progressing well; 95% business value integrated. 20 Revenues REVENUE SPLIT 21,452 cr NEW GX PRODUCT NRT «696 cr B wsvoy 03%a
Slide 14: PSAI Performance
Q4FY26 PSAI Performance Decline on account of lower API volume uptake » 12% GROSS MARGIN 19.9% vs 26.3% Q4FY26 vs C4FY25 Revenues 2912 cr BP suyoy Mf 14%Q0a DMF FILINGS 48 128 YoY decline due to lower volume uptake asry25 FY26 200 growth on account of momentum in COMO business Historical Revenues (%
Slide 15: In Summary
In Summary A diversified business model with broad based levers Strengthen Core Businesses, build future growth drivers (Peptides, Biosimilars, Consumer Health, Innovation) Advance key pipeline products (Semaglutide, Abatacept) Drive efficiencies through better operational leverage Augment organic g
Slide 16: About Key Metrics and Non-GAAP Financial Measures
About Key Metrics and Non-GAAP Financial Measures This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non- GAAP financial measures are measures of our historical performance, financial position or cash flows that are
Slide 17: Good Health Can't Wait.
(2(@ )a)e Good Health Can’t Wait.
DR Reddys Laboratories — Q4 FY26 Earnings Presentation on 6ix